INHOFE, WYDEN PRAISE SENATE PASSAGE OF I-ACT

Washington, D.C. – U.S. Sen. Jim Inhofe (R-Okla.) and U.S. Sen. Ron Wyden (D-Ore.), today praised last night’s unanimous Senate passage of the Improving Access to Clinical Trials (I-ACT) Act, a bill to allow patients with rare diseases to participate in clinical drug studies without losing their eligibility for public assistance (Supplemental Security Income (SSI) and Medicaid). 

“This bill provides potentially lifesaving treatments through clinical trials for those suffering with rare diseases, like cystic fibrosis (CF),” Inhofe said.  “This hits especially close to home for me because I have a staffer with CF who has participated in trials that seek better treatments for rare diseases.  About half of these patients are on Medicare or Medicaid and are eligible for SSI benefits.  By passing this legislation, we can make a dramatic difference in the lives of those who will gain access to potentially life-saving treatments by enrolling in clinical trials.”  

“For those suffering from rare diseases, clinical trials are often their best hope for a cure,” Wyden said.  This legislation will make sure that the small financial incentives these people receive will not be counted against them if they are on SSI or Medicaid. Patients suffering from rare diseases should not have to choose between their best hope for treatment or losing benefits, nor be denied the access more financially fortunate patients receive.

 

ADDITIONAL INFORMATION:

Under current law, the small compensation provided to trial participants, which averages around $500, is included as additional income and could cause a person to lose their public assistance benefits, like Supplemental Security Income (SSI) and Medicaid.  These benefits are crucial for patients living with rare diseases.  For instance, nearly 50% of the CF population uses SSI or Medicaid.  As a result, patients choose not to enroll in clinical trials that could dramatically improve their lives out of the fear that they may lose the benefits on which they rely. 

 

I-ACT will protect those receiving these public benefits from having small financial incentives for clinical trials counted against them. The legislation also includes safeguards to ensure against those taking advantage of the system. The bill includes a study by the Government Accountability Office to make sure the program is working and remains fair to those with rare diseases. The legislation will also sunset in five years so that Congress can reexamine the program and the GAO report on the program.

 

Cystic fibrosis used to be primarily a childhood disease because people simply didn’t live long enough to reach adulthood.  But now, thanks to the many treatments discovered through clinical trials, the average life expectancy is 37 years old.  Additionally, these advances in science allow CF patients to live more normal lives and not spend all their time in hospitals or attached to respiratory machines. The more CF patients can participate in clinical trials, the faster scientists can discover new treatments and eventually a cure.  There are more than 30 promising drugs in the research pipeline right now that the CF Foundation is calling miracle drugs so it is imperative that patients have access to clinical trials so these drugs can get on the market.

 

###